NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

CompletedN/A

Sponsor: Mayo Clinic

Conditions: Eosinophilic Asthma

Interventions: Observational

Countries: United States

The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years old.
* Diagnosis of SEA by a health care provider
* History of an absolute eosinophil count ≥ 300/mm\^3
* Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started

Exclusion Criteria:

* Age \< 18 years old.
* Pregnancy.
* Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
* Currently using or any prior use of rituximab.
* History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
* Any prior history of malignancy, autoimmune disease, or immune deficiency.
* Any other significant medical issue as determined by the principal investigator.

Locations (1)

Rochester, Minnesota, United States